SUNNYVALE, CA, March 4, 2013 /CNW/ - Accuray Incorporated (Nasdaq: ARAY), today announced highlights from the First European Conference on
stereotactic radiosurgery/stereotactic body radiation therapy
(SRS/SBRT) and image-guided intensity-modulated radiation therapy
(IG-IMRT), hosted in partnership with the Istituto Europeo di Oncologia
Milano and the Università degli studi di Milano, held in Milan, Italy
on February 22-23, 2013.
The conference "Radiation Oncology: can we still treat without image
guidance?" was attended by more than 400 healthcare professionals,
including radiation oncologists, medical physicists and hospital
administrators from 32 countries. Outcomes of recent research in areas
such as central nervous system (CNS), head and neck, breast, lung,
gastrointestinal (GI), pelvis, total marrow irradiation (TMI) and
pediatrics were presented.
The independent Scientific Committee, led by Prof. Roberto Orecchia
(Istituto Europeo di Oncologia Milano, Italy) and Prof. Eric Lartigau
(Centre Oscar Lambret, Lille, France), focused on new developments in
the field and developed an educational event to discuss the need of
image guidance for a variety of clinical indications in modern
radiation therapy. "Daily image guidance is crucial for all
high-precision treatments, also for palliative treatments" said Prof.
Eric Lartigau.
"The TomoTherapy® System provides an automatic process that makes our
daily work easy" said Prof. Dirk Verellen, UZ Brussel.
Prof. Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of
Rotterdam, said "Additionally, dose to the healthy tissue can be
strongly reduced using optimal and numerous non-coplanar beams when
treating prostate cancer" comparing non-coplanar treatments to coplanar
treatments.
"There are non-adaptive and real-time adaptive solutions, but the only
solution that adapts for target motion in real-time, available
clinically, is the CyberKnife® System", added Dr. Iciar Santa Olalla.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company
that develops, manufactures and sells personalized, innovative
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The Company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments.
Safe Harbor Statement Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to the
"safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate,
but are not limited, to clinical applications, clinical results,
patient outcomes, and the Company's leadership position in radiation
oncology innovation. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially
from expectations, including risks detailed from time to time under the
heading "Risk Factors" in the company's report on Form 10-K filed on
September 10, 2012, as updated in our Form 10-Qs filed on November 8,
2012 & February 6, 2013, and as updated periodically by our other
filings. Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
Company at the time those statements are made and/or management's good
faith belief as of that time with respect to future events. The Company
assumes no obligation to update forward-looking statements to reflect
actual performance or results, changes in assumptions or changes in
other factors affecting forward-looking information, except to the
extent required by applicable securities laws. Accordingly, investors
should not place undue reliance on any forward-looking statements.
SOURCE: Accuray Incorporated
